GeneticS Gaming l Introducing TeNziKa- / GeneticS-TenZ
Game Clip.

By: ClanGeneticSGaming

View post:
GeneticS Gaming l Introducing TeNziKa- / GeneticS-TenZ - Video

Recommendation and review posted by Bethany Smith

Mallowbops- genetics made easy
These little creatures will unravel the world of genetics! Or they may just run around 😉

By: Glen Dawkins

Read the original:
Mallowbops- genetics made easy - Video

Recommendation and review posted by Bethany Smith

GeneticS Gaming l Introducing X_KillerxFrann_X
Game Clip.

By: ClanGeneticSGaming

Link:
GeneticS Gaming l Introducing X_KillerxFrann_X - Video

Recommendation and review posted by Bethany Smith

Cancer test developer Myriad Genetics (MYGN) saw its shares climb 4% Tuesday, a move that followed word from actress Angelina Jolie that she had a double mastectomy after learning she was at high risk for breast cancer.

Jolie wrote in a New York Times column published late Monday that she underwent voluntary surgery to remove her breasts because a genetic mutation she carries means she has an up to 87% chance of developing the disease in her lifetime. The 37-year-old actress, known for movies such as "Gia" and "Lara Croft: Tomb Raider," led her announcement by noting that her mother died of breast cancer at age 56.

Salt Lake City-based Myriad has a test called the BRACAnalysis that's designed to determine a woman's risk of getting hereditary breast or ovarian cancer by looking for defects in the BRCA1 or BRCA2 genes. These mutations, the company says, are the cause of most hereditary breast cancer cases. Jolie wrote in her guest piece that she has the BRCA1 mutation.

In recent trading, Myriad, which researches tests for several cancers, including colorectal cancer and pancreatic cancer, was up $1.34 to $34.45. The stock is at its best level since mid-2009, according to Yahoo Finance data.

"Once I knew that this was my reality, I decided to be proactive and to minimize the risk as much I could," Jolie said in the column. "I made a decision to have a preventive double mastectomy. I started with the breasts, as my risk of breast cancer is higher than my risk of ovarian cancer, and the surgery is more complex."

She said she hoped other women would have the genetic test, and, should they learn they have a greater risk of getting breast or ovarian cancer, "know that they have strong options."

The National Cancer Institute expects more than 232,000 women in the U.S. to be diagnosed with some type of breast cancer this year. It predicts breast cancer will cause 39,620 female deaths. While unusual, men can also get breast cancer. About 2,200 new cases are foreseen in America in 2013, with 410 deaths. Myriad says around 7% of breast cancers are a result of the BRCA1 or BRCA2 defects.

Myriad was in the news earlier this spring by being involved in a legal case on whether patenting human genes should be allowed. A ruling by the Supreme Court will come later this year.

Read the original here:
Myriad Genetics Shares Climb After Angelina Jolie Has Mastectomy

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, May 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) announced today that Peter D. Meldrum, president and CEO, is scheduled to present at the Bank Of America Merrill Lynch 2013 Health Care Conference, at 10:00 a.m. Pacific on May 16, 2013, at the Encore at the Wynn in Las Vegas, Nevada.

The presentation will be available to interested parties through a live audio webcast accessible through a link on the investor relations section of Myriad's Web site at http://www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

See original here:
Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference

Recommendation and review posted by Bethany Smith

NEW YORK (AP) -- Shares of diagnostic test maker Myriad Genetics Inc. rose to a three-year high Tuesday, as analysts said actions by the Supreme Court and actress Angelina Jolie could both help the company.

THE SPARK: Oscar-winner Jolie disclosed Tuesday that she recently had a preventative double mastectomy after learning she faced a high risk of breast and ovarian cancer because of an inherited genetic mutation. Myriad makes a test called BRACAnalysis that looks for that mutation, and the test is the source of most of the company's revenue.

On Monday the U.S. Supreme Court upheld Monsanto Co.'s claim that a farmer in Indiana violated one of its patents on soybean seeds. The patents covered genetic modification that made the seeds resistant to Monsanto's Roundup herbicide. The high court recently heard a legal challenge to some of Myriad's genetic patents, and analysts said Monday's ruling could be good news for Myriad.

THE BIG PICTURE: BRACAnalysis looks for mutations on the breast cancer predisposition gene, or BRCA. Women with mutations on that gene have a three-to-seven times greater risk of developing breast cancer and also a higher risk of ovarian cancer. In the first quarter of 2013 almost three-quarters of Myriad's revenue came from BRACAnalysis testing.

In the U.S. 5 to 10 percent of breast cancer cases are thought to be linked to BRCA genes. Women of Eastern European Jewish descent are more likely to have faulty copies of the BRCA gene. Women who have inherited the gene are about five times more likely to get breast cancer.

In mid-April the Supreme Court heard a case related to the patenting of human genes. The case challenges two patents Myriad holds on genes related to the BRACAnalysis test. The American Civil Liberties Union and other groups have argued that the government shouldn't award patents on genes.

The Patent & Trademark office has been awarding such patents for decades. A High Court ruling is expected by June.

Analysts expect Myriad's patents to be upheld and note that even if the Supreme Court invalidates the patents, the company has other patents supporting the test.

THE ANALYSIS: In an email Cowen & Co. analyst Doug Schenkel said there is comparatively little testing of women who, like Jolie, don't have cancer or cancer symptoms but have an increased risk of the disease because of their family history or ethnic background. He said Jolie's story increases awareness of the BRACAnalysis test and of the risk some women face, and that's good news for the company.

William Blair analyst Amanda Murphy said in an email that she believes the Monsanto decision was a bigger factor in Tuesday's stock movement. She said the court recognized the investment that companies like Monsanto have to make in research and development, and that issue was also discussed during oral arguments in the Myriad case.

Link:
Myriad Genetics shares rise to three-year highs

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), a leader in oncology-focused personalized medicine, will sponsor and host a roundtable discussion at the second annual BioNJ Diagnostics & Personalized Medicine Innovation Summit on Thursday, June 6, 2013 at Sanofis U.S. headquarters in Bridgewater, NJ.

The BioNJ Diagnostics & Personalized Medicine Innovation Summit will bring together leaders from major global biotechnology and pharmaceutical companies, diagnostics companies, and emerging innovator companies to discuss the latest trends, developments and challenges in the evolution and adoption of personalized medicine. The all-day event will include company presentations, networking opportunities, and moderated panel discussions focused on research and commercialization challenges in diagnostics and personalized medicine.

Panna Sharma, CEO and President of CGI, will moderate a morning roundtable discussion that will offer a cross-industry perspective from thought leaders and operators in the frontline of driving personalized medicine. The panel will discuss trends and strategies that are emerging among leading companies in personalized medicine. Panelists include:

To learn more about the BioNJ Diagnostics & Personalized Medicine Innovation Summit, visit http://www.bionj.org/diagnostics-and-personalized-medicine-innovation-summit.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and servicessome of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.

CGIs cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.

Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, the Company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, and has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please seewww.cancergenetics.com.

Read the original here:
Cancer Genetics to Sponsor and Host Roundtable at BioNJ Diagnostics & Personalized Medicine Innovation Summit

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwired - May 14, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, announced today that Dr. Steven Quay, Chairman, CEO & President, will speak and participate on the Diagnostics panel at the Sachs Associates Cancer Bio Partnering Forum on Wednesday, May 22, 2013, at the Westin Copley Place in Boston, Massachusetts. Dr. Quay's corporate presentation will take place from 11:00 a.m. to 11:15 a.m. and the Diagnostics panel will take place from 11:55 a.m. to 12:25 p.m. Eastern Time.

Dr. Quay commented, "The Sachs Associates Cancer Bio Partnering Forum is a unique event that brings together a prestigious group of thought leaders and business development executives in the cancer biology space to discuss the latest advances in cancer diagnosis and treatments. I appreciate the opportunity to present our ForeCYTE Breast Health Test and other breast health products and laboratory services and to discussing our plans to develop an intraductal therapy for treatment of ductal carcinoma in situ (DCIS) in order to prevent breast cancer. I look forward to a highly productive meeting."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented diagnostic medical devices and patented laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA. The NRLBH provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating breast cancer cells and a tailored treatment plan for patients and their caregivers.

For additional information, please visit http://www.atossagenetics.com. You can also view a video about the ForeCYTE test here: http://vimeo.com/62214008.

Forward-Looking Statements

This press release is being issued for compliance with Regulation FD. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Read the original post:
Atossa Genetics to Present at the Sachs Associates Cancer Bio Partnering Forum and Participate on the Cancer Tech Panel

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplement to the Biologics License Application (sBLA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). The FDA is expected to take action on the application by September 14, 2013. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL.

Our goal is to broaden the ADCETRIS U.S. labeling claims to provide both patients and physicians the opportunity to incorporate ADCETRIS into additional HL and sALCL treatment settings, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. The FDAs acceptance of our sBLA submission is an important step towards making ADCETRIS available in the retreatment and extended duration setting, and we look forward to the regulatory outcome.

The sBLA is based on results from a phase 2 clinical trial with two treatment arms. One arm evaluated retreatment with ADCETRIS in patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse. The other arm evaluated extended treatment with ADCETRIS beyond 16 cycles of therapy. The sBLA submission includes updated data sets from this phase 2 trial.

Preliminary data from this trial were previously reported at the 2011 American Society of Hematology (ASH) Annual Meeting and at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include:

Retreatment:

Extended duration of treatment:

ADCETRIS is currently not approved for retreatment and extended duration beyond 16 cycles of therapy in relapsed HL and sALCL.

About Lymphoma

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that also expresses CD30.

More here:
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDA

Recommendation and review posted by Bethany Smith

BOTHELL, Wash. (AP) -- Drug developer Seattle Genetics Inc. said Tuesday the Food and Drug Administration has accepted its application to market the lymphatic cancer treatment Adcetris for some additional uses.

The Bothell, Wash., company is seeking approval for Adcetris to be used in treating patients who had previously taken the drug, stopped and then saw their disease progress or relapse. It also wants approval for Adcetris to be used in treatments that extend beyond 16 cycles of the therapy.

Seattle Genetics expects the FDA to make a decision by Sept. 14.

The company said research showed that Adcetris was generally tolerated well by patients taking it for retreatment, and nine of 23 patients who could be evaluated saw complete remission. The drug also was tolerated well when used for an extended duration.

Adcetris is the company's only marketed product, and it already is approved to treat two types of lymphoma.

Seattle Genetics shares climbed more than 2 percent, or 86 cents, to $38.19 in Tuesday morning trading, while broader indexes rose slightly. The stock has climbed more than 60 percent so far this year and hit a 52-week high of $39 last month.

Read more from the original source:
FDA accepts Seattle Genetics Adcetris application

Recommendation and review posted by Bethany Smith

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics,Inc. (ILIU) today issued financial and operational results for the first quarter ended March 31, 2013.

Revenue for the quarter ended March31, 2013 was $487,000, compared to $678,000 for the same period in 2012. The decrease is primarily attributable to decreased genetic testing revenue recognized from genetic tests processed as a result of sales through the Amway Global sales channel.

Research and development expenses were $160,000 for the three months ended March 31, 2013, compared to $446,000 for the same period in 2012. The decrease is primarily attributable to lower compensation, consulting and clinical trial costs. In the first quarter of 2013 our Chief Scientific Officer had fully transitioned to his role as Chief Executive Officer and, accordingly, related compensation costs were classified as part of selling, general and administrative expenses in the 2013 period whereas such costs had previously been classified as research and development expenses.

Selling, general and administrative expenses were $1.0 million for the three months ended March 31, 2013, compared to $1.1 million for the same period in 2012. The decrease is primarily attributable to decreased patent related legal fees and corporate legal and accounting fees as well as lower sales commissions paid to Amway Global as part of our Merchant Channel and Partner Store Agreement partially offset by higher compensation and consulting expenses.

The Company reported a net loss of $1.2 million, or $(0.03) per basic and diluted common share, for the first quarter of 2013, compared to $1.4 million or $(0.04) per basic and diluted common share for the same period in 2012.

As of March31, 2013, the Company had cash and cash equivalents of $1.1 million. As of March 31, 2013, the Company had drawn the full $14.3 million under credit facilities with Pyxis Innovations Inc., an affiliate of Alticor. This facility currently becomes due on March 31, 2014.

The Company expects that its current resources are adequate to maintain current and planned operations only through May 31, 2013. The Companys independent registered public accounting firm has included an explanatory paragraph in their opinion in connection with the 2012 audit, relating to the Company's ability to continue as a going concern. The Company has retained a financial advisor and is actively seeking additional funding. If the Company cannot obtain additional funding on acceptable terms, it may be required to discontinue operations and seek protection under U.S. bankruptcy laws.

The Company will not host a conference call/webcast today, but may determine to host a call and webcast later this month depending on the outcome of its fundraising efforts.

About Interleukin Genetics Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA). For more information please visit http://www.ilgenetics.com.

Follow this link:
Interleukin Genetics Reports First Quarter 2013 Financial Results

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwired - May 15, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company, today announced its first quarter 2013 financial results and corporate developments.

"The national rollout of our ForeCYTE Breast Health Test is proceeding well and we are pleased with the response we are getting from the physician community and from patients," stated Dr. Steven Quay, chairman, CEO and president. "We were particularly pleased to have completed an agreement with Millennium HealthCare, Inc., which provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection.Millennium has initially submitted an order for 10,000 ForeCYTE Breast Health collection kits for distribution to its network of physicians' offices in the New York Metro area and Northern New Jersey. We anticipate signing up additional distributors this year and continuing to build our internal sales and marketing team."

Corporate Highlights

First Quarter 2013 Financial Results

Revenues for the three months ended March 31, 2013, were $182,670, which included $13,440 of product revenue from the sale of MASCT Systems and $169,230 of diagnostic testing service revenue from the ForeCYTE breast health tests. This compares with total revenues of $54,713 for the first quarter ended March 31, 2012. The year-over-year increase in total revenue was driven by the national rollout of the ForeCYTE test in January 2013.

Gross profit for the three months ended March 31, 2013, was $116,206. This compares to gross profit of $27,709 for the quarter ended March 31, 2012.

Net loss for the quarter ended March 31, 2013, was $1.9 million, or $(0.14) per share, compared with net loss of $1.1 million, or $(0.09) per share, for the first quarter ended March 31, 2012. The increase in net loss was primarily attributable to an increase in general and administrative expense of $963,420, including increased expenses related to the national launch of the ForeCYTE test.

Total operating expenses were $2.1 million for the three months ended March 31, 2013, consisting of G&A expenses of $1.6 million, selling expenses of $272,575 and research and development expenses of $220,192.This compares to total operating expenses of $1.1 million for the three months ended March 31, 2012, consisting of G&A expenses of $601,452, selling expenses of $70,435 and research and development expenses of $417,990.The increase in G&A expenses of $963,420, from the first quarter of 2012 to the first quarter of 2013, is attributed to the launch of the Company's MASCT System, ForeCYTE test and ArgusCYTE test and the related growth in expenses to hire additional staff and expand the Company's operations.Atossa expects that its G&A expenses will continue to increase as it adds additional employees and incurs additional costs as a publicly traded company. Additionally, G&A costs are expected to rise as the Company increases headcount to coordinate the production and manufacture of the MASCT System, and the expected increase in service revenue.Selling expenses increased $202,140 from the first quarter of 2012 to the first quarter of 2013 as a result of hiring additional sales and marketing personnel and incurring additional marketing expenses directly and to the Company's distributor for the national launch of the ForeCYTE test.Research and development expenses decreased by $197,798 from the first quarter of 2012 to the first quarter of 2013 as a result of completion of the development of the ForeCYTE test and ArgusCYTE test in 2012 and as a result of Atossa's focus in 2013 on the national launch of ForeCYTE.

At March 31, 2013, Atossa had cash and cash equivalents of $1.4 million.

About Atossa Genetics, Inc.

Read the rest here:
Atossa Genetics Reports First Quarter 2013 Results and Operating Highlights

Recommendation and review posted by Bethany Smith

BRIDGEWATER, N.J.--(BUSINESS WIRE)--

Senesco Technologies, Inc. (Senesco or the Company) (OTC QB: SNTI), announced today that a poster presentation will be delivered at the 16th Annual Meeting of the American Society of Gene & Cell Therapy. The conference will be held May 15-18th, 2013 at the Salt Palace Convention Center in Salt Lake City, Utah. The Company will present during the Cancer-Targeted Gene & Cell Therapy: Viral Vector / siRNA-Mediated Therapies Session, which will begin Thursday, May 16, at 4:00 p.m. The poster presentation, entitled Combination Therapy with Novel Nanoparticle, SNS01-T, and Bortezomib Results in Synergistic Cytotoxicity In Vitro and In Vivo in Multiple Myeloma, will be delivered by Catherine Taylor, who is from Senesco CSO John Thompsons research laboratory at the University of Waterloo in Ontario, Canada.

About SNS01-T

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, the Mary Babb Randolph Cancer Center in Morgantown, WV, and the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, NJ. http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1

About Senesco Technologies, Inc.

Senesco, a leader in eIF5A technology, is running a clinical study with its lead therapeutic candidate SNS01-T, which targets B-cell cancers by selectively inducing apoptosis by modulating eukaryotic, translation, initiation Factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and biofuels development, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners products.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Companys ability to continue as a going concern; the Companys ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the development of the Companys gene technology; the approval of the Companys patent applications; the successful implementation of the Companys research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Companys products; the timing and success of the Companys preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the quotation of the Companys common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Companys periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Companys periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Read the original:
Senesco Announces Presentation on Combination Therapy with Novel Nanoparticle, SNS01-T, and Bortezomib Results in ...

Recommendation and review posted by Bethany Smith

STAMFORD, Conn.--(BUSINESS WIRE)--

Alliance for Cancer Gene Therapy, Inc. (ACGT), http://www.acgtfoundation.org, https://twitter.com/acgtfoundation, and https://www.facebook.com/acgtfoundation, today announced that it will be hosting an inaugural Foundation Symposium Gene and Cell Therapy For Cancer on Thursday, May 16, from 6:00 p.m. to 8:00 p.m., Ballroom B, at the 16th Annual American Society of Gene and Cell Therapy Meeting, May 15-18, Salt Palace Convention Center, in Salt Lake City, Utah. The Symposium will be co-chaired by Xandra O. Breakefield, PhD, Massachusetts General Hospital, and Savio L.C. Woo, PhD, Mount Sinai School of Medicine.

This ACGT-sponsored Symposium will present state-of-the-art lectures by leading investigators in four exceptionally promising areas of scientific research and translational development in gene and cell therapies for cancer. Over the past decade, the power of gene and cell therapies has been harnessed into novel bio-therapeutics for the treatment of many different cancers that are both effective and safe.

We are honored to partner with ASGCT and to feature some of the worlds most renowned scientists, physicians and researchers in the field of cell and gene therapy, said Barbara Netter, ACGT President and Co-Founder.

Speakers and Topics Include:

ACGT is the only not-for-profit in the U.S. dedicated solely to cancer cell and gene therapies for all types of cancer. 100% of contributions go directly to research. ACGT has funded 41 grants from public donations since its founding in 2001 totaling almost $25 million for both basic research and clinical translation. Seventeen ACGT funded research projects have been approved for human clinical trials, 11 of which are underway. To donate, please visit http://www.acgtfoundation.org or call 203.358.8000.

See original here:
Alliance for Cancer Gene Therapy to Host Inaugural Foundation Symposium at the 16th Annual American Society of Gene ...

Recommendation and review posted by Bethany Smith

Jago Punjab - Spinal Cord Injury Physiotherapy - 13 May 2013
Follow Day Night News on Facebook https://www.facebook.com/dayandnightnewss Visit Day Night News for latest news http://www.dayandnightnews.com/

By: Dayandnightnews Chd

Visit link:
Jago Punjab - Spinal Cord Injury

Recommendation and review posted by sam

Two approaches to stem cell therapy for osteoarthritis
http://www.stemcellsarthritistreatment.com There are two potential approaches of stem cell-based cartilage repair and regeneration. The first is ex vivo cart...

By: Nathan Wei

Excerpt from:
Two approaches to stem cell therapy for osteoarthritis - Video

Recommendation and review posted by simmons

Researchers from the Stanford University School of Medicine discovered that blocking the expression of a single protein in the brains of mice with a form of multiple sclerosis can delay its effects, including paralysis.

The protein, SIRT1, helps to produce the cells that make the protective myelin coating needed to transmit nerve signals in the brain. Autoimmune diseases such as multiple sclerosis damage this coating, impeding communication between nerve cells.

"We are excited by the potential implications our study has on demyelinating diseases and injuries," said Anne Brunet, associate professor of genetics at Stanford and the senior author of the research. "It's intriguing because activating SIRT1 is typically considered to be beneficial for metabolism and health, but in this case, inactivating SIRT1 can provide protection against a demyelinating injury."

The process works by developing neural stem cells in the brain into another type of cell, called an oligodendrocyte precursors. Mature oligodendrocytes wrap neurons' arms with protective myelin, helping transmit electrical impulses from one cell to another.

Brunet and her team began by injecting a lab mouse with a drug called tamoxifen, which can effectively turn the SIRT1 gene off in neural stem cells.

Over time, nerve stem cells in which SIRT1 expression had been blocked began to make proteins that looked like typical oligodendrocyte precursor cells. The lack of SIRT1 activity increased the production of cells that express oligodendrocyte-specific protein makers.

When the researchers injected normal mice and those with blocked SIRT1 expression with a compound that causes the demyelination of nerve cells just as multiple sclerosis does, the SIRT1-blocked mice had quicker recoveries than the normal mice. They were also protected for a time from the paralysis that comes after the onset of multiple sclerosis.

"Our study highlights the possibility of pharmacological manipulation of multiple nodes of the pathway to expand the population of oligodendrocyte precursors," Brunet said. "Approaches such as these could have important implications for regenerative medicine."

The research was published online May 5 in Nature Cell Biology, a journal that publishes cell-related research and papers.

The research was supported by the California Institute for Regenerative Medicine, the National Institutes of Health, a grant from the American Federation for Aging Research, a National Brain Tumor Society grant, the Glenn Foundation for Medical Research, the National Science Foundation, the Guthy-Jackson Charitable Foundation and the National Multiple Sclerosis Society.

Go here to read the rest:
Stanford: treatment delays multiple sclerosis onset in mice

Recommendation and review posted by simmons

ALLENDALE, N.J. and WASHINGTON, May 13, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that PCT has entered into a Cell Therapy Processing Customer Agreement with MedStar Georgetown University Hospital in Washington, D.C. to provide autologous and allogeneic cellular therapy services for cellular products provided by MedStar Georgetown University Hospital ("MGUH") and deliver resulting cellular therapy products to MGUH for patient care.

In April, Georgetown's Lombardi Comprehensive Cancer Center, part of MedStar Georgetown University Hospital, and the John Theurer Cancer Center, part of Hackensack University Medical Center ("HackensackUMC") in Hackensack, N.J., announced the establishment of an oncology affiliation arrangement between them to enhance patient access to innovative clinical trials, and is a significant step towards developing a clinical, translational and basic science cancer research consortium.

In its agreement with PCT, MedStar Georgetown University Hospital will use the services of PCT for processing and storage of peripheral blood progenitor cells, donor leukocytes, bone marrow and cord blood, as well as requested assaying and storage of cellular therapy product, and retrieval and transportation logistics.

"Akin to our relationship with HackensackUMC, whose engagement of PCT began over thirteen years ago, we look forward to developing a strong association with Georgetown," said Robert A. Preti, Ph.D., President and Chief Scientific Officer of PCT. "Our agreements with HackensackUMC and MedStar Georgetown University Hospital enable us to continue to play a vital part in patient care for cancers and other hematologic disorders, and to continue to provide cell products to our entire client base. Since its founding, PCT has provided cell therapy products for infusion into over 6,000 patients."

Dr. Robin L. Smith, NeoStem's Chairman and Chief Executive Officer, stated that, "NeoStem is committed to supporting and enabling the development of emerging cell therapy products. We, as well as our clients, are developing innovative therapies using the cells of our body to treat chronic diseases such as cancers, autoimmune conditions and cardiovascular disease. We are thrilled to be working with prestigious institutions such as MedStar Georgetown University Hospital and HackensackUMC to support their bone marrow transplant programs. PCT's exceptional client retention rate validates the management's commitment to Quality and Service as we look forward to future growth with our clients outside of the United States."

The Georgetown Lombardi Comprehensive Cancer Center at MedStar Georgetown University Hospital is the Washington, D.C. metropolitan region's only comprehensive cancer center, a designation from the National Cancer Institute (NCI) demonstrating its scientific excellence and the capability to integrate multi-disciplinary, collaborative research approaches to focus on the problem of cancer.

The John Theurer Cancer Center at HackensackUMC is a nationally renowned, award-winning cancer center with a strong clinical program of excellence. HackensackUMC is ranked among the 50 best hospitals in the United States and the John Theurer Cancer Center is the highest ranked cancer center in New Jersey in the 2012-13 U.S. News & World Report Best Hospitals ranking.

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at HackensackUMC is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing and support staff with specialized expertise that translates into more advanced and focused care for all patients. The John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care and medical expertiseall under one roof. Physicians at the John Theurer Cancer Center are members of Regional Cancer Care Associates, one of the nation's largest professional hematology/oncology groups. For more information please visit jtcancercenter.org.

Read this article:
NeoStem's Subsidiary, Progenitor Cell Therapy, to Provide Autologous and Allogeneic Cellular Therapy Services to ...

Recommendation and review posted by Bethany Smith

Public release date: 13-May-2013 [ | E-mail | Share ]

Contact: Tom Vasich tmvasich@uci.edu 949-824-6455 University of California - Irvine

UC Irvine Health researchers have helped discover that genes controlling circadian clock rhythms are profoundly altered in the brains of people with severe depression. These clock genes regulate 24-hour circadian rhythms affecting hormonal, body temperature, sleep and behavioral patterns.

Depression is a serious disorder with a high risk for suicide affecting approximately one in 10 Americans, according to the Centers for Disease Control, and is ranked as fourth of all diseases by the World Health Organization in terms of lifetime disability. Study findings provide the first evidence of altered circadian gene rhythms in brain tissue of people with depression and suggest a physical basis for many of the symptoms that depressed patients report.

The study which appears online this week in the Proceedings of the National Academy of Sciences involved researchers from UC Irvine Health, University of Michigan, UC Davis, Cornell University, the Hudson Alpha Institute for Biotechnology and Stanford University.

"Our findings involved the analysis of a large amount of data involving 12,000 gene transcripts obtained from donated brain tissue from depressed and normal people. We were amazed that our data revealed that clock gene rhythms varied in synchrony across six regions of normal human brain and that these rhythms were significantly disrupted in depressed patients. The findings provide clues for potential new classes of compounds to rapidly treat depression that may reset abnormal clock genes and normalize circadian rhythms," said Dr. William Bunney, Distinguished Professor of Psychiatry & Human Behavior at UC Irvine, and the study's senior author.

Circadian clock genes play an important role in regulating many body rhythms over a 24-hour cycle. Although animal data provide evidence for the circadian expression of genes in brain, little has been known as to whether there is a similar rhythmicity in human brain.

In the study, the researchers analyzed genome-wide gene expression patterns in brain samples from 55 individuals with no history of psychiatric or neurological illness and compared them to the expression patterns in samples from 34 severely depressed patients.

The investigators isolated multiple RNA samples from six regions of each brain and arranged the gene expression data around a 24-hour cycle based on time of death. Several hundred genes in each of six brain regions displayed rhythmic patterns of expression over the 24-hour cycle, including many genes essential to the body's circadian machinery.

In the end, they had a near-complete understanding of how gene activity varied throughout the day in the cells of the six brain regions they studied.

View post:
Circadian clock gene rhythms in brain altered in depression, UC Irvine Health study finds

Recommendation and review posted by Bethany Smith

Finding of disrupted brain gene orchestration gives first direct evidence of circadian rhythm changes in depressed brains, opens door to better treatment

Newswise ANN ARBOR, Mich. Every cell in our bodies runs on a 24-hour clock, tuned to the night-day, light-dark cycles that have ruled us since the dawn of humanity. The brain acts as timekeeper, keeping the cellular clock in sync with the outside world so that it can govern our appetites, sleep, moods and much more.

But new research shows that the clock may be broken in the brains of people with depression -- even at the level of the gene activity inside their brain cells.

Its the first direct evidence of altered circadian rhythms in the brain of people with depression, and shows that they operate out of sync with the usual ingrained daily cycle. The findings, in the Proceedings of the National Academy of Sciences, come from scientists from the University of Michigan Medical School and other institutions.

The discovery was made by sifting through massive amounts of data gleaned from donated brains of depressed and non-depressed people. With further research, the findings could lead to more precise diagnosis and treatment for a condition that affects more than 350 million people worldwide.

Whats more, the research also reveals a previously unknown daily rhythm to the activity of many genes across many areas of the brain expanding the sense of how crucial our master clock is.

In a normal brain, the pattern of gene activity at a given time of the day is so distinctive that the authors could use it to accurately estimate the hour of death of the brain donor, suggesting that studying this stopped clock could conceivably be useful in forensics. By contrast, in severely depressed patients, the circadian clock was so disrupted that a patients day pattern of gene activity could look like a night pattern -- and vice versa.

The work was funded in large part by the Pritzker Neuropsychiatric Disorders Research Fund, and involved researchers from the University of Michigan, University of Californias Irvine and Davis campuses, Weill Cornell Medical College, the Hudson Alpha Institute for Biotechnology, and Stanford University.

The team uses material from donated brains obtained shortly after death, along with extensive clinical information about the individual. Numerous regions of each brain are dissected by hand or even with lasers that can capture more specialized cell types, then analyzed to measure gene activity. The resulting flood of information is picked apart with advanced data-mining tools.

Lead author Jun Li, Ph.D., an assistant professor in the U-M Department of Human Genetics, describes how this approach allowed the team to accurately back-predict the hour of the day when each non-depressed individual died literally plotting them out on a 24-hour clock by noting which genes were active at the time they died. They looked at 12,000 gene transcripts isolated from six regions of 55 brains from people who did not have depression.

Read this article:
Out of Sync: Body Clocks Altered at Cell Level in Depression

Recommendation and review posted by Bethany Smith

Should the government require companies to label food that contains genetically modified organisms?

Last November, California voters rejected a ballot initiative that would require such labeling, but bills that would do so were recently introduced in both the U.S. House and Senate. Invoking the right to know, a lot of people support those bills.

In the abstract, the argument for compulsory labeling seems exceedingly powerful. But there is a risk that a compulsory label for GM food would confuse, mislead and alarm consumers, potentially causing economic harm, not least to consumers themselves.

To see the problem, we need to step back a bit. The World Health Organization defines GMOs as organisms in which the genetic material (DNA) has been altered in a way that does not occur naturally. As a result of the underlying technology, sometimes called recombinant DNA technology or genetic engineering, certain individual genes are transferred into one organism from another. GM food can potentially grow faster, taste better, resist diseases, lower reliance on pesticides, cost less and prove more nutritious.

In the U.S., GM food has become pervasive. Tomatoes, potatoes, squash, corn, sugar beets and soybeans frequently have GM ingredients. As much as 90 percent of corn, sugar beet and soybean crops are now genetically modified. In American supermarkets, genetically modified ingredients can be found in about 70 percent of processed foods. Among them are pizza, cookies, ice cream, salad dressing, corn syrup and chips. Should they all be labeled?

The argument for labeling GM foods would be compelling if they posed risks to human health. This is, of course, a scientific question, and most scientists now believe that GM food, as such, doesnt pose health risks. Last October, the American Association for the Advancement of Science spoke unequivocally. In its words, the science is quite clear: crop improvement by the modern molecular techniques of biotechnology is safe.

The American Medical Association has similarly proclaimed, The main conclusion to be drawn from the efforts of more than 130 research projects, covering a period of more than 25 years of research and involving more than 500 independent research groups, is that biotechnology, and in particular GMOs, are not per se more risky than e.g. conventional plant breeding technologies.

The World Health Organization, the National Academy of Sciences, and the Royal Society in the U.K. basically agree.

There would also be an argument for labeling if GMOs created ecological risks, rather than dangers to human health. But in 1988, the National Academy of Sciences concluded that the environmental hazards associated with GMOs are not essentially different from those associated with unmodified organisms. It found that assessment of the risks should be based not on whether the organism is genetically modified, but on the nature of the organism and the environment into which it is introduced.

The American Medical Association recently endorsed this finding.

Read the original:
Don’t Mandate Labeling for Gene-Altered Foods

Recommendation and review posted by Bethany Smith

Mutations in genes that occur spontaneously may contribute to congenital heart disease in children, according to a new study.

These mutations which arise after conception, rather than being inherited from a parent may contribute to about 10 percent of cases of congenital heart disease in children, the study said.

Congenital heart disease is a group of heart defects (such as holes, or missing parts of the heart), and is the most common type of birth defect in the United States. About 40,000 babies are born each year with congenital heart disease.

While some chromosomal abnormalities (such as Down syndrome) and infections during pregnancy are known to cause congenital heart disease, the new study shows that spontaneous gene mutations during fetal development affect the development of brain and heart, and may lead to congenital heart disease in children with healthy parents.

In the study, researchers looked at the rate of spontaneous mutations in 362 children with severe congenital heart disease, 264 healthy children and parents of both groups.

Although children in both groups had about the same number of spontaneous mutations, the locations of those mutations were markedly different in the two groups, according to the study that was published online in the journal Nature yesterday (May 12).

"The mutations in patients with congenital heart disease were found much more frequently in genes that are highly expressed in the developing heart," said study researcher Christine Seidman, a Howard Hughes Medical Institute investigator.

This finding provides insights for future research, and may someday lead to better treatment options, the researchers said.

Follow Bahar Gholipour@alterwired. Follow MyHealthNewsDaily@MyHealth_MHND, Facebook&Google+. Originally published on LiveScience.

Read the original:
Spontaneous Gene Mutations Linked to Kids' Heart Defects

Recommendation and review posted by Bethany Smith

About 10 percent of congenital heart defects may come from spontaneous rather than inherited gene mutations, according to a study that offers new insight into a condition that can range from simple to severe.

Scientists investigated the DNA of 362 newborns with serious heart defects in families where neither the parents nor the childs siblings had cardiac illness. The research, reported online yesterday in the journal Nature, found hundreds of mutations that were only in the affected children.

Congenital heart defects occur in 8 out of every 1,000 newborns in the U.S., or more than 35,000 children yearly, according to the National Heart, Lung and Blood Institute. While the findings may not help prevent the condition, identifying the variants may one day aid doctors in individualizing treatments for the children, the researchers said.

One of the most important questions when a family has a child with congenital heart disease is why? said Edwin Kirk, a clinical geneticist at the Sydney Childrens Hospital, who wasnt involved in the study. Any research that helps us understand the answer hopefully one day will be something we can apply to answering the question for individual families.

Understanding the role of the variants may eventually help improve outcomes, said co-author Christine Seidman, director of the Cardiovascular Genetics Center at Brigham and Womens Hospital in Boston, in a statement.

After we repair the hearts of these children, some children do great and some do poorly, said Seidman, who is a researcher at the Howard Hughes Medical Institute in Chevy Chase, Maryland. Scientists have suspected this might be due to differences in the underlying disease causes, she said.

The researchers compared DNA from children with heart defects and in healthy babies. Both had about the same number of so-called de novo mutations, the non-inherited variants. The sick children, though, were much more likely to carry damaging mutations at two sites within a cellular pathway known to regulate genes key in heart development.

This is really a major contribution because it gives us some hard facts about the incidence of new mutations and the rates at which they may cause congenital heart disease, said David Winlaw, a pediatric cardiac surgeon at Childrens Hospital Westmead in Sydney, in a telephone interview. The great difficulty is knowing the relevance of a specific mutation.

The next step is to narrow down the list of genes known to be associated with congenital heart disease to a list thats known to be causative, he said.

This class of proteins that they have identified as being important for congenital heart disease are involved in that regulatory process, said Sydney Childrens Hospitals Kirk in a telephone interview. Thats new. There was some hint of it from a couple of rare syndromes, but for non-syndromic congenital heart disease, I dont think we had any hint that this was going to be important.

More here:
Spontaneous Gene Mutations Tied to Child Heart Defects

Recommendation and review posted by Bethany Smith

Public release date: 13-May-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 10, 2013 MOOCs FORUM (http://www.liebertpub.com/mooc), a new journal, is the only publication dedicated exclusively to the development, design, and deployment of the game-changing Massive Open Online Courses (MOOCs). Multidisciplinary in scope, this authoritative journal has a neutral bias. Its mandate is the critical evaluation of the MOOC components and modules that are essential in creating a global and sustainable system. The Journal will be published online, with open access options, and in print by Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com).

The Editor-in-Chief of MOOCs FORUM is Nishikani (Nish) Sonwalkar, Sc.D. MOOCs FORUM content includes components and modules, roundtable discussions, interviews, case studies, model proposals, and perspectives from the leading stakeholders in the expanding and dynamic MOOCs community. Strategic thinking and re-evaluation will include ensuring the integrity for both creation and use. Existing economic models will be presented, and new models will be proposed. A robust blog will be a critical component of the Forum.

Dr. Sonwalkar is Co-Chair, EdTech Circle, MIT Enterprise Forum; Director of Research for the United States Distant Learning Association; and the Founder and Managing Director of Synaptic Global Learning, LLC. "The impetus to move our educational system to international excellence is urgent and ongoing," says Dr. Sonwalkar. "Yet the considerations relevant to the success of MOOCs have not been fully addressed. MOOCs FORUM is the catalyst for meaningful discussion and debate on the impact of these disruptive educational models."

"Education and technology have united to create MOOCs and the opportunity for unlimited and continuous global learning," says Mary Ann Liebert, President and CEO of the company that bears her name. "MOOCs FORUM is the new and authoritative space for all things MOOC."

MOOCs FORUM will examine adaptive and intelligent systems; universal design and policy; sustainable revenue models; the role of key faculty; mass customization of education; next generation of educational technology; integrity of accreditation; development of meaningful standards; clarification of misconceptions; international consideration and security; as well as differences between open and traditional online education.

###

Visit the MOOCs FORUM website to participate and sign up for email alerts (http://www.liebertpub.com/mooc).

About the Publisher

See the original post here:
MOOCs FORUM journal debuts summer 2013

Recommendation and review posted by Bethany Smith

Public release date: 13-May-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 13, 2013New approaches to applying noninvasive imaging tests such as computed tomography (CT), magnetic resonance (MR), and positron emission tomography (PET) may play a bigger role in evaluating and managing patients with diabetes. Advances in noninvasive imaging technology can assess important changes in fat composition and distribution in the body that may affect the metabolic complications and diseases associated with diabetes, including cardiovascular disease and cancer. A forward-looking Review article on "Obesity and Diabetes: Newer Concepts in Imaging" in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, highlights these emerging advances. The article is available free on the Diabetes Technology & Therapeutics website at http://www.liebertpub.com/DTT.

Kavita Garg, MD, Samuel Chang, MD, and Ann Scherzinger, PhD, University of Colorado Denver School of Medicine, Aurora, describe how sophisticated imaging techniques can be used to quantify body fat in different locations in the body. It can also help distinguish between different types of fat, which can have different effects on metabolism and pose different disease risks. In their Review article, the authors suggest that noninvasive imaging tests may be able to replace the need for biopsies, aid in early disease detection, and identify not only structural but also functional abnormalities in tissues such as heart muscle before a disorder becomes symptomatic.

"Currently, imaging techniques are not routinely done in people with diabetes," says Viswanathan Mohan, MD, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control and IDF Centre for Education, Gopalapuram, Chennai, India, in his accompanying Editorial, "Has the Time Come for Routine Imaging Studies in Diabetes?" With the changing profile of the complications of diabetes and increased incidence of diseases related to diabetes and diabetes therapies, "the article by Garg et al. is a trend-setter because this could change the way we routinely screen for these conditions in people with diabetes."

###

About the Journal

Diabetes Technology & Therapeutics is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics website at http://www.liebertpub.com/DTT.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Metabolic Syndrome and Related Disorders, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Read the original:
How can advanced imaging studies enhance diabetes management?

Recommendation and review posted by Bethany Smith